Latest breakthroughs in cancer research, treatment, and prevention
606 articoli
Zongertinib (Hernexeos) wins FDA accelerated approval for HER2-driven non-small cell lung cancer, offering a targeted oral option.
A landmark genomic analysis of 50,000 tumors maps cancer-driving mutations across tumor types, revealing critical patterns that could reshape precision oncology.
A 13-year Italian cohort study finds ultra-processed foods don't raise breast cancer risk, but alcoholic beverages do.
Pembrolizumab plus chemotherapy gains FDA approval for PD-L1-positive ovarian cancer patients who failed prior treatment.
A landmark RET-fusion lung cancer trial shows strong PFS gains but a puzzling OS signal — revealing a critical flaw in how crossover trials are designed.
A pooled analysis of 2.5 million people links higher BMI and waist size to bladder cancer risk — but only in males.
The ICARUS-LUNG01 trial sheds light on why some lung cancer patients respond to antibody-drug conjugates while others resist.
Zongertinib (Hernexeos) wins accelerated FDA approval for metastatic NSCLC with HER2 tyrosine kinase domain mutations, filling a critical treatment gap.
A phase 2 trial of datopotamab deruxtecan in 100 NSCLC patients reveals a 26% response rate and critical resistance biomarkers.
Peter Attia breaks down why prostate cancer deaths are rising despite available screening tools and how modern diagnostics can fix this.
Pre-treatment gut microbiome signatures predicted cancer recurrence in 674 melanoma patients receiving immune checkpoint blockade, with AUC up to 0.94.
New research reveals how RBM39 protein enhances DNA repair in liver cancer cells, suggesting combination therapy targets.
